The American Journal of Managed Care

Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence ...
Medscape

Zanubrutinib May Have PFS Edge Over Combo Therapy in CLL

A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.
The American Journal of Managed Care

Global Burden of CLL Decreasing, but Key Challenges Remain

CLL incidence and prevalence have decreased globally, but regional disparities exist, with high-SDI regions seeing declines and low-SDI regions experiencing stable or increasing rates. Mortality ...
Medscape

Chronic Lymphocytic Leukemia Tied to Increased Skin Cancer Risk Over 10 Years

In a Danish study, patients with chronic lymphocytic leukemia (CLL) showed a higher risk for skin cancer, metastasis, and death than matched individuals at 10 years. Researchers conducted a population ...
Targeted Oncology

Continuous Vs Fixed Duration Treatment in CLL

In the SEQUOIA trial, the BTK inhibitor zanubrutinib (Brukinsa) was delivered as a continuous dose in frontline chronic ...
WebMD

What You Need to Know About Zydelig for Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...